Publications
5491 Results
- Journal / Conference
- San Antonio Breast Cancer Symposium (Dec 6-10, 2022, San Antonio, TX, poster
- Year
- 2022
- Research Committee(s)
- Breast
- Study Number(s)
- SWOG-8814
Computerized Measurements of Nuclear Morphology Features, Mitosis Rate, and Tubule Formation from H&E Images Predicts Disease-Free Survival in Patients with HR+ & LN+ Invasive Breast Cancer from SWOG S8814
- Journal / Conference
- San Antonio Breast Cancer Symposium (December 6-10, 2022, San Antonio, TX), poster, trials in progress
- Year
- 2022
- Research Committee(s)
- Prevention and Epidemiology
- Study Number(s)
- S1904
SWOG 1904: Cluster-randomized controlled trial of patient and provider decision support to increase chemoprevention informed choice among women with atypical hyperplasia or lobular carcinoma in situ (MiCHOICE)
- Journal / Conference
- Cancer Research Vol 83, Issue 5_Suppl 1 March 2023; San Antonio Breast Cancer Symposium (Dec 6-10, 2022, San Antonio, TX, Spotlight Poster Discussion
- Year
- 2022
- Research Committee(s)
- Symptom Control and Quality of Life
- Study Number(s)
- S1714
Incidence of Chemotherapy Induced Peripheral Neuropathy in Patients with Early-Stage Breast Cancer Receiving Taxane Therapy: SWOG S1714 (NCT# 03939481)
- Journal / Conference
- San Antonio Breast Cancer Symposium (Dec 6-10, 2022, San Antonio, TX), oral
- Year
- 2022
- Research Committee(s)
- Breast
- Study Number(s)
- S1007
Race and Clinical Outcomes in the RxPONDER Trial (SWOG S1007)
- Journal / Conference
- San Antonio Breast Cancer Symposium (Dec 6-10, 2022, San Antonio, TX), poster
- Year
- 2022
- Research Committee(s)
- Breast
- Study Number(s)
- S1007
Impact of HER2 low status on clinical outcomes in participants (pts) with 1-3 positive lymph nodes (LN), hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < 25 randomized to endocrine therapy (ET) +/- chemotherapy (CT): results from SWOG S1007 (RxPONDER)
- Journal / Conference
- Society for Immunotherapy of Cancer (SITC) (Nov 8-12,2022, Boston, MA), poster
- Year
- 2022
- Research Committee(s)
- Early Therapeutics and Rare Cancers
- Study Number(s)
- S1609
A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in Patients with Gestational Trophoblastic Disease
- Journal / Conference
- ASH Annual Meeting (Dec 10 thru 13, 2022, New Orleans, LA), oral
- Year
- 2022
- Research Committee(s)
- Lymphoma
- Study Number(s)
- CTSU/E1412, E4494, S1001
Development of a Conditional Event-Free Survival Tool in Diffuse Large B-Cell Lymphoma
- Journal / Conference
- ASCO Quality Care Symposium (September 30 - October 1, 2022, Chicago, IL), oral presentation
- Year
- 2022
- Research Committee(s)
- Cancer Care Delivery
- Study Number(s)
- S1415CD
Intervention non-adherence in a pragmatic randomized trial of a standardized order entry for colony stimulating factor prescribing
- Journal / Conference
- ASH Annual Meeting (Dec 10 thru 13, 2022, New Orleans, LA), poster
- Year
- 2022
- Research Committee(s)
- Leukemia
How many stratification factors are reasonable and can there be too many? Evaluation of analysis strategies in the context of a randomized Phase 2 trial in acute myeloid leukemia within the myeloMATCH platform
- Journal / Conference
- ASH Annual Meeting (Dec 10 thru 13, 2022, New Orleans, LA), oral presentation
- Year
- 2022
- Research Committee(s)
- Lymphoma
- Study Number(s)
- CTSU/E1411